Skip to main content
Sumitomo Pharma Co., Ltd. logo

Sumitomo Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 4506 ISIN · JP3495000006 LEI · 529900D60UKVYLJ2OJ79 T Manufacturing
Open in API
Filings indexed 94 across all filing types
Latest filing 2025-11-04 Interim / Quarterly Rep…
Country JP Japan
Listing T 4506

About Sumitomo Pharma Co., Ltd.

https://www.sumitomo-pharma.com/

Sumitomo Pharma Co., Ltd. is a research and development-driven pharmaceutical company focused on creating innovative pharmaceuticals and healthcare solutions. The company's primary therapeutic areas are Psychiatry & Neurology and Oncology, with additional activities in diabetes, rare diseases, and women's health. A key aspect of its R&D strategy is the integration of established expertise in small molecule drug discovery with pioneering modalities such as regenerative medicine and cell therapy. The company's mission is to translate scientific innovation into real-world solutions to contribute to the betterment of healthcare and fuller lives for people worldwide, with a strategic business focus on Japan and the United States.

Recent filings

Filing Released Lang Actions
半期報告書－第206期(2025/04/01－2025/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and operational updates for the interim period (April 1, 2025, to September 30, 2025). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2026
2025-11-04 Japanese
訂正臨時報告書
M&A Activity Classification · 100% confidence The document is a 'Temporary Report' (臨時報告書) filed with the Kanto Local Finance Bureau in Japan. It details a corporate restructuring involving a company split (absorption-type company split) and the transfer of shares of a subsidiary to Marubeni Global Pharma. This type of filing is a mandatory regulatory disclosure under the Financial Instruments and Exchange Act of Japan for significant corporate events, such as changes in subsidiaries or material impacts on financial performance. Since it is a specific regulatory filing for material events and does not fit into the other categories like 10-K or ER, it is classified as a Regulatory Filing.
2025-10-31 Japanese
臨時報告書
AGM Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 that it is being filed because resolutions were passed at the '第205期定時株主総会' (205th Annual General Meeting) held on June 26, 2025. Section 2 details the resolutions, which include changes to the articles of incorporation (transitioning to an audit committee company structure) and the election/remuneration of directors. The core content is the official results of the shareholder vote (votes for, against, abstentions, and outcome) for the AGM resolutions. This content directly corresponds to the reporting of voting results from a general meeting. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is moderate, but the content is the definitive result summary, not just an announcement of a future report (RPA/RNS).
2025-06-27 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is extremely short (587 characters) and appears to be a confirmation statement regarding the appropriateness/accuracy of a previously filed document, specifically referencing the '有価証券報告書' (Securities Report, which is equivalent to a 10-K in the Japanese context) for the fiscal period ending March 31, 2025. The header explicitly states the filing type as '確認書' (Confirmation Document) submitted to the Kanto Local Finance Bureau Director, based on Article 24-4-2, Paragraph 1 of the Financial Instruments and Exchange Act. Since this is a confirmation document about a major filing (like a 10-K) rather than the full report itself, and it doesn't fit neatly into the standard US SEC forms (10-K, 10-Q, etc.), it falls best under the general regulatory announcement category. Given the options, 'RNS' (Regulatory Filings) is the most appropriate fallback for a specific, non-standard regulatory confirmation filing that is not a core financial report, management discussion, or audit report. FY 2025
2025-06-26 Japanese
内部統制報告書－第205期(2024/04/01－2025/03/31)
Governance Information Classification · 100% confidence The document is titled '内部統制報告書' (Internal Control Report) in the header section, which is explicitly mandated by Article 24-4-4, Paragraph 1 of the Financial Instruments and Exchange Act ('金融商品取引法第24条の４の４第１項'). It discusses the framework, scope, criteria, procedures, and results of the assessment of internal controls over financial reporting ('財務報告に係る内部統制'). This type of report, focusing on internal controls and often filed alongside the annual financial statements, aligns best with the 'Audit Report / Information' category (AR), as it deals with the assurance and structure surrounding financial reporting, distinct from the full Annual Report (10-K) or a simple Earnings Release (ER). The document structure and content strongly suggest a formal regulatory filing concerning internal control assurance.
2025-06-26 Japanese
有価証券報告書－第205期(2024/04/01－2025/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains a formal cover page detailing the fiscal year (2024-04-01 to 2025-03-31), the company name (Sumitomo Pharma Co., Ltd.), and the filing date (2025-06-26). The presence of XBRL tags and the formal structure confirm it is the comprehensive annual financial report. FY 2025
2025-06-26 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.